Patient characteristics
| Subjects n | 51 |
| Age yrs | 62.6±9.1 |
| Female sex | 10 (19.6) |
| Stage | |
| IIA | 2 (3.9) |
| IIB | 3 (5.9) |
| IIIA | 19 (37.3) |
| IIIB | 9 (17.6) |
| IV | 18 (35.3) |
| Diagnosis | |
| Adenocarcinoma | 40 (78.4) |
| NSCLC | 11 (21.6) |
| Diagnostic procedure | |
| EBUS-TBNA | 26 (51.0) |
| Bronchoalveolar lavage | 1 (2.0) |
| Bronchial biopsy | 5 (9.8) |
| Pericardial fluid | 1 (2.0) |
| Bone metastasis | 2 (3.9) |
| Surgery | 16 (31.4) |
| Lymph node metastasis by EBUS-TBNA | 36 (70.6) |
| Adenocarcinoma | 29 (56.9) |
| Unspecified NSCLC | 7 (13.7) |
| Metastatic lymph node region sampled | |
| 4R | 10 (19.6) |
| 4L | 2 (3.9) |
| 7 | 22 (43.1) |
| Lobar node | 2 (3.9) |
| EGFR analysis feasible | |
| Adenocarcinoma EBUS-TBNA samples | 20 (39.2) |
| NSCLC EBUS-TBNA samples | 6 (11.8) |
| Other biopsy/cytology samples | 25 (49.0) |
| EGFR mutation status | |
| Present | 5 (9.8) |
| Exon 19 | 2 (3.9) |
| Exon 21 | 3 (5.9) |
| Wild-type | 46 (90.2) |
| Mutation identified only in EBUS-TBNA sample | 2 (3.9) |
Data are presented as mean±sd or n (%), unless otherwise indicated. NSCLC: nonsmall cell lung cancer; EBUS-TBNA: endobronchial ultrasound-guided transbronchial needle aspiration; EGFR: epidermal growth factor receptor.